Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 (COVID-Aging)
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study
Sponsor: University Hospital, Strasbourg, France
Terminated
difficulty in recruiting
Other terminated trials from University Hospital, Strasbourg, France
- Healthy Control Subjects · Apr 2025
- Cystic Fibrosis-related Diabetes · Phase PHASE4 · Jan 2025
- Kidney Transplant Recipients · Nov 2024
- Diagnosed With Uretral Fibroscopy · Sep 2024
- Patients with Colorectal Cancer · Phase NA · Sep 2024
See all terminations from University Hospital, Strasbourg, France
Listed as NCT04359953, this PHASE3 trial focuses on COVID-19 Infection and remains terminated or withdrawn. Sponsored by University Hospital, Strasbourg, France, it has been updated 7 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Strasbourg, France
For direct contact, visit the study record on ClinicalTrials.gov .